Participated previously in our preliminary study (EK 1044/2020) and continued Dupilumab treatment since then. Long-term use of Dupilumab since the preliminary study will be assessed based on patient self-report, as there is currently no clinical test or laboratory parameter available to objectively verify treatment duration.
Signed and dated informed consent has been obtained
Current therapy with Dupilumab
You may not be if
Pregnancy (as determined by urine ß-HCG test)
Clinically significant abnormal laboratory values and active infection (Tbc, HIV, hepatitis A/B/C)
History of malignancy or immunodeficiency
Chronic obstructive lung disorders (COPD), other obstructive lung disorders (bronchiolitis)
Need for systemic corticosteroid therapy 1 month prior to screening visit
Eosinophilic pneumonia and Churg-Strauss Syndrome
Previous anaphylaxis and contraindications against ASA as outlined in the official prescribing information.
